tapebrief
ALGN · Q2 2025
ALGN · Q4 2025

ALGN · Q3 2025 Earnings

Cautious

Align Technology

Reported October 29, 2025

30-second summary

30-second take: Revenue of $995.7M (+1.8% YoY) cleared the $965–985M guide by $10.7M above the high end on Clear Aligner volume of 647.8K (+4.9% YoY), and management raised FY25 Clear Aligner volume growth to mid-single digits from low-single digits. But GAAP operating margin landed at 9.7% — below the 10.5–11.5% guide — on $36.6M of restructuring plus $88.3M aggregate non-cash impairments, and FY revenue growth was held at "flat to slightly up." The volume number rescues the cyclical-vs-structural debate from the bear case, but the North American retail channel "remains mixed," deferred Systems & Services revenue fell 13.9% YoY, and management deferred all 2026 top-line commentary in Q&A.

Headline numbers

EPS

Q3 FY2025

$2.61

Revenue

Q3 FY2025

$1.00B

+1.8% YoY

Gross margin

Q3 FY2025

64.2%

Operating margin

Q3 FY2025

9.7%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$1.00B+1.8%$1.01B-1.6%
EPS$2.61—$2.49+4.8%
Gross margin64.2%—69.9%-570bps
Operating margin9.7%—16.1%-640bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ3 FY2025$965M to $985M$995.7M+$10.7M to $30.7M above guideBeat
GAAP Gross MarginQ3 FY202564% to 65%64.2%-0.8pts to -0.2pts below guideMissed
GAAP Operating MarginQ3 FY202510.5% to 11.5%9.7%-0.8pts to -1.8pts below guideMissed
Non-GAAP Operating MarginQ3 FY2025approximately 22%23.9%+1.9pts above guideBeat

New guidance

MetricPeriodGuideYoY
RevenueQ4 FY2025$1,025M to $1,045M—
GAAP Gross MarginQ4 FY202565.5% to 66.0%—
Non-GAAP Gross MarginQ4 FY2025approximately 71.0%—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Clear Aligner Volume Growth
FY2025
low-single digitsmid-single digitsraised from low-single digits to mid-single digitsRaised
GAAP Operating Margin
FY2025
13% to 14%around 13.6% to 13.8%+0.6pts to +0.8pts at midpointRaised
Capital Expenditures
FY2025
$100M to $125Mapproximately $100M-$25M at the high endLowered

Reaffirmed unchanged this quarter: Revenue Growth (flat to slightly up from 2024), Non-GAAP Operating Margin (slightly above 22.5%)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Clear Aligner$0.806B+2.4%
Imaging Systems and CAD/CAM Services$0.19B-0.6%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Clear Aligner Volume647.8 thousand cases
Clear Aligner Volume YoY Growth+4.9%
Clear Aligner Volume QoQ Growth+0.5%
Clear Aligner Revenue Per Case$1,245
Teens and Kids Clear Aligner Volume256.0 thousand cases
Teens and Kids YoY Growth+8.3%
Invisalign Trained Doctors88,155
Non-GAAP Operating Margin23.9%

Management tone

Narrative arc: Q2 Restructuring narrative replaces growth narrative → Q3 Volume reaccelerates but North America retail still broken.

The diagnosis of weakness has narrowed and crystallized rather than broadened. Last quarter management framed the problem as patient demand plus doctor behavior plus financing across North America, France, and Germany — a worsening structural read. This quarter management said "While the North American retail doctor channel remains mixed, we continue to see strength in our other key geographies" and confirmed in Q&A that nine of the top ten countries grew YoY, with DSO growth exceeding 20% in some areas. The problem is now isolated to one channel in one geography. That is a tighter, more defensible diagnosis — but it is also an admission that the U.S. retail orthodontist is not the growth customer Align is planning around anymore.

The 2026 framing has hardened into a margin commitment with no top-line anchor. Last quarter management offered ≥100bps operating margin improvement in FY26 as the one forward anchor; this quarter, asked directly by Stifel's John Block for directional 2026 top-line guidance, management declined and reiterated only the margin commitment. "For fiscal 2026, we expect these restructuring actions as well as other initiatives to improve our GAAP and non-GAAP operating margins by at least 100 basis points year over year." The absence of any top-line color into next year, paired with a clean volume beat this quarter, says management is unwilling to underwrite the reacceleration as durable.

The product narrative has shifted from defense to capability. The ClinCheck Live Plan disclosure — "can reduce the Invisalign treatment planning cycle from days to minutes" — and the evolution from 5×5 to 3×3 to no-refinement product tiers were framed by Stifel as doctor confidence improving. That is the first piece of offensive product positioning in three quarters of defensive commentary, though it carries an implicit admission about prior workflow inefficiency.

The hedging in the outlook is still material. Forward statements remain qualified by "assuming no circumstances occur beyond our control, such as foreign exchange, macroeconomic conditions, and changes to our current applicable duties." Combined with the deferred-revenue compression in Systems & Services and the inability to commit to 2026 top-line, the cautious tone of Q2 has been refined, not replaced.

Recurring themes management leaned on this quarter:

Geographic diversification with APAC and EMEA growth offsetting North America weaknessTeens and kids segment as bright spot with record 40% mix of total clear aligner casesDigital ecosystem expansion (iTero, ExoCAD, ClinCheck Live) driving adoptionDSO channel as reliable growth engine with double-digit year-over-year performanceRestructuring and operational consolidation underway with near-term margin pressureAI and automation as long-term competitive advantages despite current execution complexity

Risks management surfaced:

North American retail doctor channel market softness and mixed activityForeign exchange headwinds impacting reported resultsTariff and tax policy uncertainty (US tariffs, UK VAT changes)Macroeconomic conditions affecting patient financing and doctor purchasingDeferred revenue declining significantly suggesting slower customer commitment durations

Q&A highlights

John Block · Stifel

ASP was down Q-over-Q despite expectations for sequential increase; what drives Q4 ASP improvement, and what are thoughts on pricing environment and timing of no-refinement plan rollout?

Q3 ASP decline driven by geographic mix shift (China lower ASP, Europe higher ASP). Q4 will reverse this as Europe becomes larger percentage and China smaller. No-refinement plan represents continuous evolution from 5x5 to 3x3 products, reflecting improved technology confidence and doctor optionality rather than phase transformation.

China has lower ASP than EuropeGeographic mix shift: China larger in Q3, smaller in Q4; Europe larger in Q4Product evolution: 5x5 to 3x3 to no-refinement approachDoctors increasingly opt to proceed without refinements due to improved technology and confidence

Jeff Johnson · Baird

Confirmation of double-digit YoY growth in EMEA and APAC clear aligner volumes; inquiry on specific percentages to back into North America decline magnitude and changes in U.S. retail behavior regarding gross receipts vs. case closures.

Double-digit growth in EMEA/APAC confirmed and widespread across top 10 countries including India, Turkey. Specific percentages declined. No material change in gross receipts vs. CCA data; U.S. retail remains consistently challenged but did not worsen in Q3. Consumer confidence decline noted in September/October but behavioral patterns remain consistent.

Top 10 countries grew double digits YoYIndia and Turkey showing strong performanceNo primary or material change in gross receipts vs. case closure analysisU.S. retail consistently challenged; DSO business continued to grow while retail accounts struggled

Jason Bednar · Piper Sandler

Updated perspective on China competitive landscape and VBP implementation; clarification on 'positioning' strategy. Deeper inquiry on U.S. retail weakness—if not consumer spending, is it lower-ROI business sensitivity, and how much effort defending vs. pursuing margin expansion?

China VBP positioning underway but timing and provincial scope still unclear; portfolio structured for Tier 3/4 cities. U.S. retail weakness framed as market expansion opportunity not just defense. DSOs succeeding via digital scanning, visualization, competitive pricing, and financing solutions (HFD). Margin expansion pursued alongside market growth via technology innovation addressing 75% of population with malinclusion.

VBP implementation timing and scope still uncertain in ChinaPortfolio restructured for Tier 3/4 cities in China75% of population has untreated malinclusionDSOs utilizing digital scanning, visualization, competitive pricing, and HFD financing

Michael Cherney · Lyric Partners

What is the biggest gating factor limiting North America retail customer recovery to normalized demand, and what can Align proactively do beyond waiting for macro recovery?

North America retail weakness tied to economic factors affecting retail doctors more than business-oriented DSOs. Gating factors include consumer confidence (structural issue). Align's strategy: push DSO penetration, downstream marketing (zip code targeting), leveraging brand and field force to drive patient flow to retail doctors. Cannot wait for macro; must drive action.

Canada experienced more pressure than U.S.Economic issues hit retail customers more than business-oriented DSOsDSO penetration strategy prioritizedZip code-targeted downstream marketing planned

John Block · Stifel

2026 margin guidance (100 bps improvement) received, but seeking directional top-line guidance for 2026 given mixed growth dynamics (half of clear aligner business double-digit, half flat/down; Systems/Services mature).

No 2026 top-line guidance provided. Reiterated strong Q4 confidence and nine of top 10 countries growing YoY. Biggest issue is North America retail; DSO growth over 20% in some areas. Commitment to solidify growth momentum but deferred specific 2026 forecasts.

Nine of top 10 countries grew YoY in Q3DSO growth exceeds 20% in some areasNorth America retail identified as primary headwindStrong global presence expected to continue

Answers to last quarter's watch list

Clear Aligner volume growth turning negative. Volume printed +4.9% YoY at 647.8K cases — a clean acceleration from Q2's +0.3% — and management raised FY25 volume growth to mid-single digits from low-single digits. The cyclical-vs-structural debate tilts cyclical on this data point. Status: Resolved positively
Revenue per case trajectory. Clear Aligner ASP was $1,245 vs. $1,250 in Q2, a modest step-down attributed by management to China mix being larger in Q3. Q4 ASP is guided up sequentially as Europe mix normalizes. The structural mix-shift narrative has been refined into a geographic-mix mechanic, but the floor under ASP remains unproven. Status: Continue monitoring
Q3 revenue vs $975M midpoint. Revenue came in at $995.7M, beating the high end of the $965–985M range by $10.7M (+2.1% above midpoint). The reset bar was met and cleared. Status: Resolved positively
Restructuring charge containment within $150–170M. Q3 carried $36.6M in restructuring and other charges plus $88.3M in aggregate non-cash items (impairment of assets held for sale, depreciation on assets to be disposed of, inventory impairment). FY non-cash charges are now guided at $145–155M with cash outlay around $45M. The cash component is well contained; the non-cash component is larger and more granularly disclosed than the original $150–170M envelope implied. Status: Continue monitoring
North America and Western Europe stabilization. North America retail "remains mixed" and Canada is worse than the U.S. per management. EMEA is now in the double-digit-growth bucket alongside APAC — Europe has stabilized but North America has not. Status: Resolved negatively (for North America); Resolved positively (for Western Europe)
FY26 ≥100bps operating margin improvement commitment. Reaffirmed verbatim this quarter for both GAAP and non-GAAP. No walk-back. Status: Resolved positively

What to watch into next quarter

Q4 revenue vs $1,035M midpoint and FY volume settling in mid-single digits. Guidance implies +3.9% QoQ; a clean print would consolidate the Q3 volume reacceleration. A miss would put the raised FY volume guide back at risk.

Q4 GAAP operating margin recovery to 15.3–15.8%. That is a 560–610bps QoQ jump from Q3's 9.7%. Achieving it depends on restructuring charges rolling off; any slippage signals the cost program is bleeding into FY26.

Systems & Services deferred revenue trajectory. Down 13.9% YoY ($30.9M) on shorter-duration scanner service contracts. Whether this stabilizes or accelerates is the cleanest forward read on capex appetite among Align's doctor base.

First 2026 top-line color. Management declined to commit on the Q3 call. The Q4 call is where they will either anchor 2026 revenue or extend the refusal — the latter would be a meaningful negative signal given the ≥100bps margin commitment is already on the table.

North American retail metrics. Watch for any quantification of U.S. retail doctor volume trends or DSO penetration share. If U.S. retail erodes further while DSO grows 20%+, the channel mix shift becomes the structural story for ALGN regardless of total volume growth.

China VBP scope and provincial implementation. Most evasive Q&A topic this quarter; any quantified guidance on Tier 3/4 city volume or ASP impact would be material.

Sources

  1. Align Technology Q3 2025 earnings press release, October 29, 2025 — https://www.sec.gov/Archives/edgar/data/1097149/000109714925000075/algn-q325earningspressrele.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.